2-47475270-G-T
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PM1PM2PM5PP3_StrongPP5
The NM_000251.3(MSH2):c.2005G>T(p.Gly669Cys) variant causes a missense, splice region change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 15/27 in silico tools predict a damaging outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G669D) has been classified as Pathogenic.
Frequency
Consequence
NM_000251.3 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 11 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MSH2 | NM_000251.3 | c.2005G>T | p.Gly669Cys | missense_variant, splice_region_variant | 12/16 | ENST00000233146.7 | NP_000242.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MSH2 | ENST00000233146.7 | c.2005G>T | p.Gly669Cys | missense_variant, splice_region_variant | 12/16 | 1 | NM_000251.3 | ENSP00000233146 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Data not reliable, filtered out with message: AC0;AS_VQSR AF: 0.00 AC: 0AN: 1457756Hom.: 0 Cov.: 33 AF XY: 0.00 AC XY: 0AN XY: 725068
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Oct 17, 2018 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 30, 2024 | The c.2005G>T variant (also known as p.G669C), located in coding exon 12 of the MSH2 gene, results from a G to T substitution at nucleotide position 2005. The amino acid change results in glycine to cysteine at codon 669, an amino acid with highly dissimilar properties. However, this change occurs in the last base pair of coding exon 12, which makes it likely to have some effect on normal mRNA splicing. This variant has been identified in an additional proband whose Lynch syndrome-associated tumor demonstrated loss of MSH2/MSH6 expression by IHC (external laboratory communication) and, in a study that quantified tumor characteristics to assess pathogenicity for germline mismatch repair gene variants, this variant was reported in an individual whose Lynch syndrome-associated tumor demonstrated loss of MSH2/MSH6 expression on immunohistochemistry (IHC; Ambry internal data; Li S et al. J. Med. Genet. 2020 Jan;57:62-69). In a massively parallel cell-based functional assay testing susceptibility to a DNA damaging agent, 6-thioguanine (6-TG), this variant was reported to be functionally neutral (Jia X et al. Am J Hum Genet, 2021 Jan;108:163-175). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site and will result in the creation or strengthening of a novel splice donor site. Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Carcinoma of colon Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The MSH2 c.2005G>T variant was not identified in the literature nor was it identified in dbSNP, ClinVar, MutDB, LOVD 3.0, Insight Colon Cancer Gene Variant Database, Zhejiang Colon Cancer Database, Mismatch Repair Genes Variant Database, or Insight Hereditary Tumors Database. The variant was identified in Cosmic (1x in liver cancer), UMD-LSDB (1x as likely causal). The variant was not identified in the following control databases: the 1000 Genomes Project, the NHLBI GO Exome Sequencing Project, the Exome Aggregation Consortium (August 8th 2016), or the Genome Aggregation Database (Feb 27, 2017). The c.2005G>T variant occurs in the last three bases of the exon. This position has been shown to be part of the splicing consensus sequence and variants involving this position sometimes affect splicing. In addition, 5 of 5 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predict a greater than 10% difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more pathogenic role for this variant. This variant is classified as likely pathogenic. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 28, 2018 | Variant summary: MSH2 c.2005G>T (p.Gly669Cys) variant involves the alteration of a conserved last nucleotide of exon 12. Several computational tools predict a significant impact on normal splicing: Five predict the variant abolishes a 5 splicing donor site. If transcribed without splice alteration, the variant would result in a non-conservative amino acid change located in the loop region within Walker boxes in ATPase domain (domain V) in the encoded protein sequence, with five of five in-silico tools predicting damaging effect of the variant on protein function. However these predictions have yet to be confirmed by functional studies. The variant was absent in 243882 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.2005G>T in individuals affected with Lynch Syndrome and no experimental evidence demonstrating its impact on protein function have been reported. However, a different variant affecting the same nucleotide position (c.2005G>C, p.Gly669Arg) was reported to be found in 2 LS patients who showed absent expression of MSH2 protein by immunohistochemistry; this report might indicate the importance of this nucleotide- or amino acid position (PMID: 22371642). Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. One laboratory classified the variant as likely pathogenic, and one laboratory classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic. - |
Hereditary nonpolyposis colorectal neoplasms Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 28, 2019 | This variant is not present in population databases (ExAC no frequency). This sequence change replaces glycine with cysteine at codon 669 of the MSH2 protein (p.Gly669Cys). The glycine residue is highly conserved and there is a large physicochemical difference between glycine and cysteine. This variant also falls at the last nucleotide of exon 12 of the MSH2 coding sequence, which is part of the consensus splice site for this exon. This variant has been reported in an individual in the Universal Mutation Database (Unpublished data). ClinVar contains an entry for this variant (Variation ID: 486870). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Nucleotide substitutions within the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at